Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome
Jia Huang(Henan University), Yan Degenhardt(Cancer Research Institute), Phyllis A. Gimotty(University of Pennsylvania), Joseph R. Testa(Fox Chase Cancer Center), George Coukos(Ludwig Cancer Research), Dionyssios Katsaros(McGill University Health Centre), Renee Ward(Cancer Research Institute), Andrew K. Godwin(The University of Melbourne), Joel Greshock(Cancer Research Institute), Theresa A. Colligon(Cancer Research Institute), Katherine L. Nathanson(Translational Therapeutics (United States)), Lin Zhang(Simon Fraser University), Yan Wang(North Sichuan Medical University), Heini Lassus(Helsinki University Hospital), Barbara L. Weber(Cancer Research Institute), Ralf Bützow(Helsinki University Hospital)
Cited by 107
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Patterns of somatic mutation in human cancer genomes
|Nature|2007|3.1k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k